Biomarkers for gastrointestinal adverse events related to thiopurine therapy  

作　　者：Giulia Zudeh Raffaella Franca Gabriele Stocco Giuliana Decorti 

机构地区：[1]Department of Life Sciences,University of Trieste,Trieste 34127,Italy [2]Department of Medical,Surgical and Health Sciences,University of Trieste,Trieste 34149,Italy [3]Institute for Maternal and Child Health I.R.C.C.S Burlo Garofolo,Trieste 34137,Italy

出　　处：《World Journal of Gastroenterology》2021年第38期6348-6356,共9页世界胃肠病学杂志（英文版）

摘　　要：Thiopurines are immunomodulators used in the treatment of acute lymphoblastic leukemia and inflammatory bowel diseases.Adverse reactions to these agents are one of the main causes of treatment discontinuation or interruption.Myelosuppression is the most frequent adverse effect;however,approximately 5%-20%of patients develop gastrointestinal toxicity.The identification of biomarkers able to prevent and/or monitor these adverse reactions would be useful for clinicians for the proactive management of long-term thiopurine therapy.In this editorial,we discuss evidence supporting the use of PACSIN2,RAC1,and ITPA genes,in addition to TPMT and NUDT15,as possible biomarkers for thiopurine-related gastrointestinal toxicity.

关 键 词：THIOPURINES Gastrointestinal adverse effects Biomarkers PACSIN2 RAC1 ITPA 

分 类 号：R969.3[医药卫生—药理学]